programmed cell death protein 1-activated T cells + programmed cell death protein 1 inhibitor

Programmed cell death protein 1-activated T cells + programmed cell death protein 1 inhibitor is an investigational combination immunotherapy regimen developed by researchers at Zhongshan Hospital, Fudan University, primarily for the treatment of advanced hepatocellular carcinoma (HCC). The therapy involves the adoptive transfer of autologous T cells that have been harvested from the patient and activated *ex vivo* using a specific protocol (referred to as aT-cells or PD-1-activated T cells) to enhance their anti-tumor potency. This cell therapy is administered in conjunction with a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, such as sintilimab or camrelizumab. The PD-1 inhibitor works synergistically by blocking the PD-1/PD-L1 signaling axis, which prevents the exhaustion of both the re-infused aT-cells and the patient's endogenous T-cell population within the immunosuppressive tumor microenvironment. This dual approach aims to provide a more robust and sustained immune response against liver cancer cells compared to monotherapy.

Other names

aT-cells + PD-1 inhibitorPD-1-activated T cells plus PD-1 blockadePD1-activated T cells plus PD-1 blockadePD 1-activated T cells plus PD-1 blockadePD-1-activated autologous T cells + sintilimabPD-1-activated autologous T cells + camrelizumab